EGFR-emblicanin A exhibited a higher RMSD plateau varying from 0.3 to 0.4 Å, indicating a higher degree of flexibility and confirmation changes, while EGFR-penta-o-galloylglucose showed a decreasing trend, suggesting a gradual convergence to a more stable confirmation over time.
← all excerpts
Exploring the therapeutic potential of <i>Emblica officinalis</i> natural compounds against hepatocellular carcinoma (HCC): a computational approach.
1
—
—